ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,673.96
0.31%
Dow Jones
44,544.66
-0.75%
Gold vs US Dollar
2,798.49
0.00%
Brent Oil
76.385
0.00%
Bitcoin
99,959.27
-0.70%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Intellia Therapeutics Inc (NTLA) Share Price

NTLA Intellia Therapeutics Inc

10.2619
-0.2481 (-2.36%)
01 Feb 2025 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Intellia Therapeutics Inc NASDAQ:NTLA NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.2481 -2.36 10.2619 10.00 14.20 10.65 10.11 10.54 2,163,175 05:00:07   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 In Vitro,in Vivo Diagnostics 36.28M -481.19M -4.7246 -2.18 1.07B
 Type  Size  Price  Time  Units 
 20 410 10.2619 00:56:42 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore NTLA News
31/01/202521:17EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
23/01/202522:41EDGAR2Form 3 - Initial statement of beneficial ownership of securities
22/01/202512:30GLOBEIntellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
10/01/202512:30EDGAR2Form 8-K - Current report
09/01/202521:00GLOBEIntellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
07/01/202522:23EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
07/01/202522:22EDGAR2Form 4 - Statement of changes in beneficial ownership of securities
Period
Draw mode
Data Downloads for NTLA

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Intellia Therapeutics Inc Articles

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads